Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMKLR1 | Q99788 | 1/20 | 0.34 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.33 |
| ▸ | RXRA | P19793 | 1/20 | 0.33 |
| ▸ | RXRB | P28702 | 1/20 | 0.33 |
| ▸ | RXRG | P48443 | 1/20 | 0.33 |
| ▸ | DRD1 | P21728 | 1/20 | 0.33 |
| ▸ | ATR | Q13535 | 3/20 | 0.32 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 3/20 | 0.31 |
| ▸ | CPT1A | P50416 | 1/20 | 0.31 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.30 |
| ▸ | MTOR | P42345 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5802425 | 0.92 | RXRA (0.35) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL5374181 | 0.90 | DRD1 (0.33) | RXRARXRBRXRGDRD1ATR | |
| SCHEMBL5651015 | 0.90 | DRD1 (0.33) | RXRARXRBRXRGDRD1ATR | |
| SCHEMBL5373140 | 0.88 | CPT2 (0.35) | RXRARXRBRXRGDRD1ATR | |
| SCHEMBL5373368 | 0.88 | DRD1 (0.34) | RXRARXRBRXRGDRD1ATR | |
| SCHEMBL5398150 | 0.86 | DGAT2 (0.32) | RXRARXRBRXRGDRD1ATR | |
| SCHEMBL5373361 | 0.86 | DGAT2 (0.36) | RXRARXRBRXRGDRD1ATR | |
| SCHEMBL5374237 | 0.86 | CNR1 (0.32) | RXRARXRBRXRGDRD1DGAT2 | |
| SCHEMBL5377590 | 0.86 | ALDH1A1 (0.34) | DRD1 | |
| SCHEMBL14554188 | 0.86 | MAP4K4 (0.36) | RXRARXRBRXRGDGAT2CPT1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1871364-A1 | METHODS FOR TREATING OR PREVENTING ACUTE MYELOGENOUS LEUKEMIA | Signal Pharmaceuticals LLC (US) | 2008-01-02 | — | — | EP | disclosed |
| US-7220771-B2 | Methods of using indazole derivatives as JNK inhibitors | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-05-22 | — | — | US | disclosed |
| US-7211594-B2 | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-05-01 | — | — | US | disclosed |
| US-7208513-B2 | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-04-24 | — | — | US | disclosed |
| US-20070060616-A1 | Methods for treating, preventing and managing chronic lymphocytic leukemia with indazole compounds | SIGNAL PHARMACEUTICALS, LLC | 2007-03-15 | — | — | US | disclosed |
| US-20070004777-A1 | Methods for treating or preventing acute myelogenous leukemia | SIGNAL PHARMACEUTICALS, LLC | 2007-01-04 | — | — | US | disclosed |
| US-20060258706-A1 | Solid forms of a JNK inhibitor | CELGENE CORPORATION | 2006-11-16 | — | — | US | disclosed |
| WO-2006102363-A1 | METHODS FOR TREATING OR PREVENTING ACUTE MYELOGENOUS LEUKEMIA | SIGNAL PHARMACEUTICALS, LLC (US) | 2006-09-28 | — | — | WO | disclosed |
| EP-1618093-A2 | INDAZOLE DERIVATIVES AS JNK INHIBITORS | Signal Pharmaceuticals LLC (US) | 2006-01-25 | — | — | EP | disclosed |
| US-6897231-B2 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, INC. (US) | 2005-05-24 | — | — | US | disclosed |
| US-20050009876-A1 | Indazole compounds, compositions thereof and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC | 2005-01-13 | — | — | US | disclosed |
| WO-2004094388-A2 | INDAZOLE DERIVATIVES AS JNK INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2004-11-04 | — | — | WO | disclosed |
| US-20040127536-A1 | Methods for treating an inflammatory condition or inhibiting JNK | SIGNAL PHARMACEUTICALS, LLC | 2004-07-01 | — | — | US | disclosed |
| US-20040077877-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, INC. | 2004-04-22 | — | — | US | disclosed |
| EP-1358154-A2 | PYRROLIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF NEURAMINIDASES | Abbott Laboratories (US) | 2003-11-05 | — | — | EP | disclosed |
| EP-1313711-A2 | INDAZOLE DERIVATIVES AS JNK INHIBITORS | SIGNAL PHARMACEUTICALS, INC. (US) | 2003-05-28 | — | — | EP | disclosed |
| WO-2002010137-A9 | INDAZOLE DERIVATIVES AS JNK INHIBITORS | SIGNAL PHARM INC (US) | 2003-02-06 | — | — | WO | disclosed |
| US-20020103229-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, LLC | 2002-08-01 | — | — | US | disclosed |
| WO-2002010137-A2 | INDAZOLE DERIVATIVES AS JNK INHIBITORS | SIGNAL PHARMACEUTICALS, INC. (US) | 2002-02-07 | — | — | WO | disclosed |
| WO-2001028996-A2 | PYRROLIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF NEURAMINIDASES | ABBOTT LABORATORIES (US) | 2001-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127536-A1 | Methods for treating an inflammatory condition or inhibiting JNK | MAPK1, MAP3K1, MAPKAPK2 | CMKLR1 664/4885CYP4F2 4056/4885CYP4A11 1771/4885 |
| US-20040077877-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | MAP3K7, MAP3K1, MAP3K8 | CMKLR1 2764/4885CYP4F2 2542/4885CYP4A11 913/4885 |
| US-20070060616-A1 | Methods for treating, preventing and managing chronic lymphocytic leukemia with indazole compounds | BCL9, MCL1, INMT | CMKLR1 2502/4885CYP4F2 2444/4885CYP4A11 277/4885 |
| US-20070004777-A1 | Methods for treating or preventing acute myelogenous leukemia | MCL1, NPM1, FLT3 | CMKLR1 1080/4885CYP4F2 969/4885CYP4A11 297/4885 |
| US-20020103229-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | MAP3K7, MAP3K1, MAP3K8 | CMKLR1 2764/4885CYP4F2 2542/4885CYP4A11 913/4885 |
| US-20060258706-A1 | Solid forms of a JNK inhibitor | MAPK1, MAP3K1, MAP3K20 | CMKLR1 1368/4885CYP4F2 4104/4885CYP4A11 1881/4885 |
| US-20050009876-A1 | Indazole compounds, compositions thereof and methods of treatment therewith | GPR119, JAK3, IGF1R | CMKLR1 1126/4885CYP4F2 3286/4885CYP4A11 819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.